Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
obesity, BioAge Labs
BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq
California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a weight loss drug.
Obesity drug developer BioAge Labs aims up to $640 million valuation in upsized US IPO
(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from investors.
BioAge Labs aims to raise $180M from IPO, private placement to fund obesity trials
BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the metabolic-focused biotech will use to push its lead obesity prospect through the clinic. | BioAge Labs is eyeing about $180 million in initial proceeds from an IPO and a private placement,
IPO, MNTN and Ryan Reynolds
Ryan Reynolds's MNTN Explores Going Public as the IPO Market Shows Signs of Thawing
After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, including Reynolds' MNTN.
Ryan Reynolds’s ad tech firm MNTN looks to Morgan Stanley for 2025 IPO
Reynolds became CCO of the firm after the company acquired his agency, Maximum Effort, in 2021. MNTN, a company that sells targeted TV advertising technology, may be working with Morgan Stanley on an initial public offering (IPO) as the firm considers its future.
Ryan Reynolds’ MNTN Is Said to Tap Morgan Stanley for 2025 IPO
MNTN, a connected TV advertising platform that counts Hollywood star Ryan Reynolds as its chief creative officer, has picked Morgan Stanley to work on an initial public offering, according to people familiar with the matter.
FierceBiotech
3d
BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
3d
BioAge seeks nearly $200 million in initial public offering
BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Helene death toll rises
'Days of Our Lives' star dies
Vance’s Pennsylvania rally
Rescue mission launched
Chief adviser subpoenaed
ISR strikes Lebanon again
Malibu coast earthquake
CA stove labels bill vetoed
Hospitalized for burns
NC dam failure ‘imminent’
'SNL' launches 50th season
Congestion fee bid denied
Faces fine to end Brazil ban
Houthis attack US warships
High-end brothel plea
On Hezbollah leader's killing
Deposition in AI suit
NY ballot appeal rejected
Haney sues Garcia
Dow closes at record high
KY sues Express Scripts
Diocese reaches settlement
121st loss of the season
Human rabies death in MN
Van Gogh paintings attacked
UNC digital IDs blocked
Congressional Gold Medal
ICE: Convicts roaming free
Feedback